Market Research Report
Biopharmaceutical CMO & CRO Market Size Analysis Report By Source, By Service Type (Contract Manufacturing, Contract Research), By Product (Biologics, Biosimilars), And Segment Forecasts, 2019 - 2025
|Published by||Grand View Research, Inc.||Product code||544772|
|Published||Content info||240 Pages
Delivery time: 2-3 business days
|Biopharmaceutical CMO & CRO Market Size Analysis Report By Source, By Service Type (Contract Manufacturing, Contract Research), By Product (Biologics, Biosimilars), And Segment Forecasts, 2019 - 2025|
|Published: May 8, 2019||Content info: 240 Pages||
The global biopharmaceutical cmo & cro market size is expected to reach USD 37.8 billion by 2025, at a CAGR of 7.7%, according to a new report by Grand View Research, Inc. The market is significantly driven by the growing interest of conventional drug developers in biological therapeutics. At present, outsourcing has become a cost-saving strategy for small to medium sized biomanufacturers, as it helps eliminate the need for establishing expensive specialized facilities or hiring and training personnel.
The decline in R&D productivity and increased development costs has resulted in high pressure on biopharmaceutical manufacturers pertaining to short-term earnings and profit margins. This, in turn, has created lucrative opportunities for the Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to accelerate their business operations.
Robustness of venture capital investments is one of the important supportive factors that have created growth opportunities for CMOs. Venture capital funds are considered more reliable than public equity. Increasing availability of venture funds for life sciences is expected to further bolster the growth of CMOs. However, these CMOs and CROs are facing competition from in-house departments of pharmaceutical and biotechnology companies. Several big pharma companies like Novartis announced to keep their biomanufacturing process in-house.
Mammalian cell line-based bioproduction systems held the largest market share in terms of revenue in 2018. Factors responsible for this estimated share include growth in mammalian system titers and yields. CMOs are engaged in standardizing their mammalian systems, thereby driving the revenue growth of the segment. Contract research service is anticipated to be the fastest growing segment over the forecast period, attributed to increasing investment in research programs for development of novel therapeutics. The CMOs are majorly benefitted by the continuous market expansion of biologics.
Several biopharma companies from U.S. are considering Asian countries for development of pharma products. This is primarily due to the growing costs of R&D in their home country and the presence of low-cost production facilities and cheap labor in Asian countries. The key players are also involved in establishing mutually beneficial alliances with other emerging CMOs to scale up their production capabilities.
Further key findings from the report suggest:
Mammalian cell line-based bioproduction system accounted for the largest market share in terms of revenue in 2018
Plant-based expression systems are developed and explored as a cost-effective alternative for the production of large molecules
Contract manufacturing services accounted for the largest market share owing to the presence of wide range of services from cell line development to final packaging of the product
In recent times, biologics manufacturing is becoming more specialized, as a result, CMOs have become an integral part of the biologics production strategies of clients, leading to biologics gaining a large share of the biopharmaceutical CMO & CRO market
North America biopharmaceutical research industry is recognized as a leader in biopharmaceutical innovations, thereby resulting in the large share of this region
Some key CMOs are Lonza; Boehringer Ingelheim GmbH; Patheon; Samsung BioLogics; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.